Discovery Assay Technologies
The owner of this homepage is:
Dr. Eberhard Krauß
Since 2018, Dr. Eberhard Krauß is working for Evotec (France) as a group leader in target validation and early drug discovery (oncology). In 2014, Eberhard co-founded and implemented VIB Discovery Sciences enabling to translate basic research outcomes into early drug discovery programmes.
However, he likes occasionally to teach courses or hold lectures, in most cases privately and outside of his regular working time. He annually teaches together with a partner, or a small team of instructors in the past, the one-day ‘High-Content Screening’ Short Course at SLAS. Further courses have been focusing on ‘Target Identification and Validation’, ‘RNA Interference in Practice’, or ‘Good Practice in Assay Development’.
Since 2008, he has been supporting scientists during various positions in industry (Tibotec, Janssen Pharmaceutica) and academia (Universität Würzburg) in technology selection, target identification & validation, assay development & screening, and drug discovery.
Between 2003 and 2008, Eberhard Krauß was establishing and heading the central high-content screening labs (HT -Technology Development Studio, TDS) at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, a unique academic facility dedicated to technology development and screening to support internal and external large-scale functional and chemical genomics projects.
Before, he held responsible positions for 6 years in biotech industry at Cenix BioScience GmbH (Germany) and Cyclacel Ltd. (Scotland, UK) dealing with RNA interference (RNAi) and drug discovery, respectively. Before joining a medical research centre in Munich running a gene therapy project in restenosis, he earned his Ph.D. at the LMU München (Munich) studying gene regulation in eye lens development. By training he is a microbiologist.
Eberhard Krauß was for many years member of the Academic Outreach Committee (AOC) of the Society of Biomolecular Screening (SBS), now SLAS. After a few years of a break, he was re-elected in 2012 to serve the Steering Committee of the Joint Working Group ‘Chemical Biology’ of Dechema, GBM, GDChand DPhG in Germany.
Disclosures:
This is the private, non-commercial homepage of Dr. Eberhard Krauß solely to share non-proprietary knowledge and insights to some technologies that are of importance for target discovery, chemical biology and drug discovery.
Dr. Eberhard Krauß is acting completely in his own name here and not on behalf any of his current or past employers. All content of this homepage, the imported presentation slides and the statements of Dr. Eberhard Krauß are of private nature and do not necessarily reflect the view of any of his current or past employers. This homepage has been entirely generated during private time and at private costs of Dr. Eberhard Krauß.
Various commercial products have been described or depicted on this private homepage; however, this does not represent an endorsement. Dr. Eberhard Krauß has no equity holding in any of these companies.
ChemBioCon is a private place holder, not a business or commercial entity.
Contact:
Dr. Eberhard Krauß
E-mail: eberhard.krausz@web.de
www.chembiocon.de, Wiesbaden, Germany